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Abstract 
Over  the  last  two  decades  umbilical  cord
blood  (UCB)  transplantation  (UCBT)  is
increasingly  used  for  a  variety  of  malignant
and benign hematological and other diseases.
The main factor that limits the use of UCB to
low  weight  recipients,  mainly  children  and
adolescents, is its low progenitor cell content.
Various  alternatives  have  been  exploited  to
overcome this difficulty, including the trans-
plantation of two UCB units (double umbilical
cord blood transplantation, dUCBT). Following
dUCBT,  donor(s)  hematopoietic  stem  cells
(HSC) can be detected in the peripheral blood
of the recipient as soon as 14 days post-trans-
plantation.  Sustained  engraftment  of  HSC
from one or both donors can be observed- dom-
inance  or  mixed  chimerism  respectively,
although  single  donor  unit  dominance  has
been  observed  in  over  85%  of  patients.  The
underlying  biology,  which  accounts  for  the
interactions  both  between  the  two  infused
UCB  units-  cooperative  or  competitive,  and
with the recipient’s immune system, has not
been elucidated.
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Since the first dUCBT in 2005, its safety and
efficacy  have  been  examined  in  over  993
patients.1 Compared to single UCB, dUCBT is
associated with: i) Higher incidence of acute
GvHD grade II, though not higher treatment-
related mortality or chronic GvHD; ii) Lower
leukemia relapse for patients with good dis-
ease  status  (complete  remission  1-2).1-3 In
more than 85% of patients undergoing dUCBT,
regardless of the conditioning scheme, long-
term hematopoiesis is derived from one of the
infused cord blood units.1,4 The time-frame for
the engraftment of the dominant unit has not
yet been elucidated. However, in over 80% of
patients, single unit dominance can be detect-
ed  three  weeks  post-transplantation.4 Mixed
chimerism can be detected in the one fifth of
the  patients  under  reduced  intensity  condi-
tioning (RIC) regimens4. Cases whereby dom-
inance reversion or loss of single unit domi-
nance in favor of mixed donor chimerism have,
also, been reported.5,6 There are mathematical
models that can provide approximations of the
chimerism pattern following dUCBT, but the
prediction  of  the  winning  unit  seems  to  be
impossible (atmospheric noise theory).7,8
In attempting to explain single unit domi-
nance in dUCBT, both intrinsic properties of
the  infused  units  and  immune  interactions
between  the  recipient  and  the  donors  are
taken into consideration. However, the former
are  difficult  to  rationalize,  especially  since
variations regarding the in vitro proliferation
potential of UCB CD34+ cells have been report-
ed.9 Nevertheless,  it  has  been  demonstrated
that  there  is  no  association  between  domi-
nance and number of nucleated cells, CD34+,
CD3+,  degree  of  HLA/sex  mismatch,  ABO
group, viability, order and route of infusion.4
However, Avery et al reported an association
between higher CD3+ cell dose and unit domi-
nance in patients undergoing dUCBT following
myeloablative regime.10 Cell viability is a con-
troversial  issue.  Clinical  experience  shows
that  cord  blood  with  viability  less  than  70%
could be easily engrafted, although Scaradavou
et al. recently analyzed 46 cord blood trans-
plants and suggested that low CD34+ cell via-
bility (<75%) UCB units in dUCBT have low
probability  of  engraftment.11 In  this  study,
infusion  of  one  high  (>75%)  and  one  low
(75%) CD34+ viability unit resulted in engraft-
ment  of  the  high  viability  unit.  Either  unit
engrafted  in  patients  transplanted  with  two
units of high (27 patients) or low viability (1
patient). It has, also, been proposed that the
order  of  infusion  may  influence  unit  domi-
nance.  Intravenous  infusion  of  the  units  in
dUCBT with 3.5-4.5 hour interval promotes the
engraftment of the first infused unit.5 Bearing
in  mind  that  the  HSC  could  home  to  the
endosteal niche in under five hours post-infu-
sion, it is likely that even a short interval may
contribute  to  the  dominance  of  the  first
infused unit.12 Furthermore, the tight balance
between proliferation and quiescence of the
resident  stem  cells  in  the  endosteal  niche
could influence the long-term engraftment of
the dominant unit.13 Clinical trials comparing
the  different  routes  of  infusion  have  not
demonstrated any selective advantage between
intravenous and intrabone administration.14
On the other hand, there is increasing evi-
dence that single unit dominance in dUCBT
recipients is the result of the immune-mediat-
ed rejection of the non-engrafting unit.5 It has
been demonstrated in vivo that naive CD8+ T
cells in one UCB unit expanded and differenti-
ated into IFN-γ secreting effector T cells that
specifically recognized the non-engrafting unit
and caused its rejection.9 However, these cyto-
toxic  cells  were  transiently  detected  in  the
peripheral blood of dUCBT recipients with sin-
gle  unit  dominance  and  are,  therefore,  not
likely to be the sole cause of rejection. The
chronic  GvHD  in  patients  with  mixed
chimerism  following  RIC  regimens  suggests
graft-versus-graft  interactions  between  the
two units and between the units and the recip-
ient.5 In cases with mixed chimerism, more
studies are needed to clarify the interactions
between the three different elements, the two
infused  units  and  the  recipients.  A  recent
study  provides  further  evidence  in  favor  of
immune  interactions  between  the  infused
units, since recipients of units closely (7-10 to
10-10) HLA-matched to each other, undergoing
myeloablative  regime,  were  more  likely  to
demonstrate  initial  engraftment  of  both
units.10 
Bearing  in  mind  the  incompatibility
between  the  two  units,  the  allo-reactive
response could be triggered by immune system
components, such as minor H antigens that
are  shared  between  the  UCB  units.  This
hypothesis  could  account  for  the  enhanced
graft-versus-leukemia (GvL) effect associated
with dUCBT, if the progenitor cells of the non-
engrafted  unit  have  similar  major  or  minor
antigens with the leukemic cells. It is not clear
whether  HLA  disparity  contributes,  too.  The
identification  of  the  antigens  expressed  on
HSCs that activate the T-cells of the dominant
unit  is  ongoing.  Furthermore,  the  in  utero
development of CD4+ T cells, which can be tol-
erant to non-inherited maternal allo-antigens
present in the other UCB unit, could account
for  the  mixed  chimerism.9,15 Studies  on
murine models revealed that the addition of
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the corresponding mononuclear cells or CD34–
to CD34+ cells restored single-unit dominance
following dUCBT, suggesting that unit domi-
nance is probably associated with T-cell medi-
ated  graft-versus-graft  immune  interactions.
Other immune-related mechanisms can, also,
be  involved,  such  as  killer-immunoglobulin-
like  receptor-ligand  incompatibility  and  NK-
cell activation.16,17
Several clinical trials have shown that co-
transplantation  of  third-party  mesenchymal
stromal  cells  (MSCs)  derived  from  various
sources  (bone  marrow,  placenta)  could
improve the engraftment, although marginal-
ly.18 In murine models, dUCBT accompanied by
co-infusion  of  MSCs  improved  engraftment
and reduced the extent of single unit domi-
nance in favor of mixed chimerism.19 MSCs
have  immunosuppressive/immunomodulatory
properties and exert trophic activity- via the
secretion of immune-related molecules, with
which  they  can  modulate  T-cell  responses.19
Furthermore,  culture-expanded  MSCs  do  not
express MHC class II surface markers and co-
stimulatory molecules, so that they can neither
function as antigen-presenting cells nor can
they be directly involved in T-cell triggering.20
Whether  the  improved  engraftment  in  the
presence of MSCs is associated with improved
homing or increased bone marrow tropism or
promotion of immunotolerance remains to be
determined. 
In conclusion, intrinsic factors of the stem
cells not yet fully understood, such as homing
to the niche, as well as, prior therapy, intensi-
ty of conditioning regime, trophic effects, host
factors  and  interactions  between  the  grafts
and the host are all likely contribute to the pat-
tern of chimerism in dUCBT. The implication
of immune-mediated mechanisms could be of
significance in the context of leukemia; if the
dominant unit can be predicted prior to trans-
plantation; a non-engrafting unit sharing host
antigens  not  present  on  the  engrafting  unit
can  be  selected  to  promote  the  GvL  effect.
Ongoing clinical trials and prolonged patient
follow-up  will  contribute  in  clarifying  the
underlying biology of dUCBT and demonstrate
its safety and efficacy. 
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